TB-500 for Horses: Equine Recovery Protocol Guide

What Is TB-500 and Why Is It Used in Horses?

TB-500 is the synthetic version of the active region of Thymosin Beta-4 (Tβ4) — a naturally occurring protein found in virtually every tissue in your horse's body. After injury, your horse's cells release Thymosin Beta-4 to initiate healing. TB-500 works by amplifying this signal, dramatically accelerating the natural repair process.

In equine sports medicine, TB-500 has become one of the most widely used regenerative peptides for:

Superficial and deep digital flexor tendon injuries
Suspensory desmitis and ligament injuries
Muscle tears and strain
Soft-tissue damage from high-intensity training
Performance maintenance between competition seasons

Published clinical evidence A blinded, placebo-controlled clinical trial by Watts et al. (Vet Surg, 2012, PMID: 22571474) demonstrated that intralesional thymosin β4 significantly improved fiber alignment and reduced re-injury rates in horses with superficial digital flexor tendonitis. This is the highest-quality equine evidence for any peptide currently available.

How TB-500 Works

TB-500 (the N-acetyl-LKKTETQ fragment) acts primarily by sequestering G-actin — a process that promotes cell migration, wound contraction, and new tissue formation. Specifically it:

Upregulates metalloproteinases (MMPs) — enzymes that remodel scar tissue into properly organized collagen fibers
Promotes muscle fiber repair — activates satellite cells that regenerate damaged muscle
Reduces systemic inflammation via NF-κB downregulation — without suppressing the immune system
Stimulates angiogenesis — new blood vessel growth into damaged tissue for faster healing
Accelerates tendon fiber alignment — the Watts 2012 trial showed measurably improved fiber architecture vs. placebo

Critically, TB-500 works systemically — a single SC injection distributes throughout the body, reaching injured tissues even when the injection site is distant from the injury.

TB-500 Dosing Protocol for Horses

The standard equine protocol follows a two-phase approach. All doses are given subcutaneously, typically in the lateral neck or lateral thorax.

Phase	Dose	Frequency	Duration	Purpose
Loading	10–20 mg SC	Twice weekly	4 weeks (8 injections)	Saturate tissue receptors; initiate accelerated repair cascade
Maintenance	10 mg SC	Once weekly	Ongoing (4–12 weeks)	Sustain healing momentum; reduce re-injury risk
Performance maintenance	10 mg SC	Every 2 weeks	Competition season	Proactive soft-tissue support during high-workload periods

      Injection site rotation
      Rotate injection sites across the lateral neck (both sides), lateral thorax, and gluteal region. Never inject in the same spot twice consecutively. Use a 25–27 gauge, 5/8–1 inch needle for subcutaneous injection.
    

Combined BPC-157 + TB-500 Protocol (REJUV Stack)

Many equine practitioners use TB-500 alongside BPC-157 for synergistic effects — BPC-157 addresses local tissue repair while TB-500 provides systemic recovery support. PeptaGen offers a combined REJUV stack containing both peptides plus GHK-Cu and KPV.

Conditions Treated with TB-500 in Horses

Condition	Expected Response	Typical Protocol Duration
Superficial Digital Flexor Tendonitis	Improved fiber alignment, reduced re-injury rate	8–12 weeks total
Deep Digital Flexor Tendonitis	Slower response; combine with BPC-157	12–16 weeks
Suspensory Desmitis	Reduced inflammation, improved fiber organization	8–12 weeks
Muscle Tears (Grade 1–2)	Faster return to work; reduced scar tissue	6–8 weeks
Post-fracture soft-tissue repair	Adjunct to surgical/orthopedic management	8–12 weeks

Safety, Contraindications & Doping Considerations

Safety profile:

TB-500 has an excellent safety profile in horses. The Watts 2012 clinical trial reported no adverse events in treated horses. The peptide is a fragment of a naturally occurring protein — it metabolizes into normal amino acids.

Contraindications:

Active malignancy — TB-500 promotes cell migration and angiogenesis; theoretical risk in cancer
Pregnancy — insufficient data; not recommended in broodmares

Competition/doping considerations:

      Important for competition horses
      TB-500 is detectable in equine urine and plasma by LC-MS. A 2012 study (Ho et al., J Chromatogr A, PMID: 23084823) confirmed detection after a single 10 mg SC dose. TB-500 is prohibited by USEF, FEI, and most racing authorities. Ensure adequate washout before competition. Check your specific sport's current prohibited list.
    

Why PeptaGen for Equine TB-500?

Pharmacy-grade manufacturing — not a research chemical supplier. USP 797 sterile compounding.
10 mg vials — optimal for equine dosing (single-vial loading dose)
Cold-chain shipping — temperature-controlled packaging for all orders
Licensed pharmacist-compounded — formulated by a clinical pharmacist with biochemistry credentials
Protocol support — equine dosing guide included with every order

TB-500 for Horses: The Gold Standard Equine Recovery Peptide